Minireviews
Copyright ©The Author(s) 2021.
World J Clin Oncol. Oct 24, 2021; 12(10): 868-881
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.868
Table 1 Human epidermal growth factor receptor 2 overexpression and gene amplification in endometrial cancer
Histological type
HER2 overexpression
HER2 gene amplification
Ref.
Overall4%-69%18%-80%[19,45,55]
Endometrioid (low grade)rarerare[29,45]
Endometrioid (high grade)8%-31%15%-29%[29,45]
Serous carcinoma20%-60%13%-29%[29,42,43,45]
Clear cell carcinoma33%-70%22%-50%[29,55]
Carcinosarcoma0-25%13%-20%[38,48-51]
Table 2 Human epidermal growth factor receptor 2-targeted therapies for uterine serous carcinoma and carcinosarcoma
Trial
Phase
Participants
Treatment
Efficacy/indentifer
GOG181B[55]IIHER2-positive EC (n = 33, endometrioid: 13, serous: 11, clear: 3, others: 6)TrastuzumabORR 0%, mPFS 1.84 mo, mOS 7.8 mo
GOG229D[56]IIPersistent or recurrent EC (n = 31, endometrioid: 16, serous: 7, clear: 3, others: 5, HER2-positive: n = 2)LapatinibmPFS 1.82 mo, mOS 7.33 mo
Fader et al[46,57]IIHER2-positive USC (n = 61)carboplatin+paclitaxel+trastuzumab vs carboplatin+paclitaxelmPFS 12.9 mo vs 8.0 mo, mOS 29.6 vs 24.4 mo
MyPathway[25]Phase IIa Multiple basket studySolid tumor(HER2-positive EC, n = 7)Trastuzumab+pertuzumabORR 0%(EC)
Li et al[59]IIHER2 amplified cancer (endometrial cancer: n = 18)Trastuzumab emtansineEndometrial cancers: CR 2, PR 2
DESTINY-PanTumor02[77]IIHER2 expressing tumor (urothelial, biliary tract, cervical, endometrial, ovarian, pancreatic, rare tumors)Trastumab deruxtecanNCT04482309
Veneris[78]IHER2-positive USCTrastuzumab deruxtecan+olaparibNCT04585958
Banerji et al[61]IDose-expansion cohort: HER2-positive breast, gastric, urothelial, endometrial cancerSYD-985 (Trastuzumab duocarmazine)Endometrial cancer: ORR 39%, mPFS 4.3 mo
Koper[79]IHER2-positive solid tumorSYD-985 (Trastuzumab duocarmazine)+NiraparibNCT04235101
Hendriks[80]IIHER2-positive endometrial cancerSYD-985 (Trastuzumab duocarmazine)NCT04205630
STATICE[52]IIHER2-positive UCSTrastuzumab deruxtecanUMIN00002956 (NCCH1615)
Makker[81]IIHER2-positive endometrial cancer, UCSZW25NCT04513665
Ramos[82]IIHER2-positive solid tumorsTucatinib and trastuzumabNCT04579380